Mandate

Vinge acts as lead advisor to EQT in connection with its acquisition of Life Sciences Partners

Vinge acts as lead advisor to EQT AB in connection with its acquisition of Life Sciences Partners, a leading European life sciences venture capital firm with approximately EUR 2.2 billion of assets under management

LSP, headquartered in Amsterdam, the Netherlands, is a venture capital firm that invests in innovative companies with strong scientific and clinical rationale across several life sciences strategies. LSP was founded in 1998 and today is one of Europe’s largest and most experienced life sciences investment firms. LSP employs a large number of professionals across its offices in Amsterdam, Munich and Boston. Over the past two decades, LSP has invested in over 150 life sciences companies, generated strong returns, and built a top-performing life sciences franchise. As part of EQT, the LSP team will be able to continue to operate in the same successful manner as they have been operating over the past two decades.

EQT AB will acquire 100 percent of the LSP management companies and 20 percent of the right to carried interest in select LSP funds. In addition, EQT AB will be entitled to 35 percent of the carried interest of future funds. The upfront consideration amounts to EUR 450 million (on a cash- and debt free basis) comprising of 25 percent cash and 75 percent EQT AB publicly traded shares.

Vinge’s team consisted of Christina Kokko, Karl Klackenberg and Milad Kamali (M&A), Sofie Bjärtun (Equity Capital Markets), Emma Johansson and Johan Wahlbom (Competition) and Emma Stuart-Beck and Caroline Krassén (Regulatory) and Ellinor Gyllenhammar (VDR Expert). Vinge has advised EQT together with Debevoise & Plimpton LLP (Investment Funds) and Loyens & Loeff (Dutch law)

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025